Twelve patients with metastatic clear cell renal cancer received a course of tamoxifen. Three showed stable disease for a period from 2 to 12 months and 1 a mixed response for a short time. It does not appear that tamoxifen may be a useful agent in the treatment of metastatic renal cell carcinoma.
Get full access to this article
View all access options for this article.
References
1.
AlbertoP., SennH.J.: Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs. Cancer, 33: 1226–1229, 1974.
2.
BloomH.J.G.: Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. Br. J. Cancer, 25: 250–265, 1971.
3.
BloomH.J.G., DukesC.E., MitchleyB.C.V.: Hormone dependent tumours on the kidney. The oestrogen-induced renal tumour of the Syrian hamster. Hormone treatment and possible relationship to carcinoma of the kidney in man. Br. J. Cancer, 17: 611–645, 1963.
4.
BloomH.J.G., RoeF.J.C., MitchleyB.C.V.: Sex hormones and renal neoplasia. Inhibition of tumor of hamster kidney by an estrogen antagonist, an agent of possible therapeutic value in man. Cancer, 20: 2118–2124, 1967.
5.
ConcolinoG., MarocchiA., ContiC., TenagliaR., Di SilverioF., BracciU.: Human renal cell carcinoma as a hormone dependent tumor. Cancer Res., 38: 4340–4344, 1978.
6.
FerrazziE., CarteiG., De BesiP., FornasieroA., PalùG., PaccagnellaA., SperandioP., FosserV., GrigolettoE., FiorentinoM.: Tamoxifen in disseminated breast cancer. Tumori, 63: 463–468, 1977.
7.
FeunL.G., DrelichmanA., SinghakowintaA., VaitkeviciusV.K.: Letters: Phase II study of nafoxidine in the therapy for advanced renal carcinoma. Cancer Treat. Rep., 63: 149–150, 1979.
8.
HahnR.G., BauerM., WolterJ., CreechR., BennettJ.M., WamplerG.: Phase II study of single-agent therapy with megestrol acetate, VP-16–213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Cancer Treat. Rep., 63: 513–515, 1979.
9.
JordanV.C.: Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer, 12: 419–429, 1976.
10.
KirkmanH.: Autonomous derivatives of estrogen-induced renal carcinomas and spontaneous renal tumors in the Syrian hamster. Cancer Res., 34: 2728–2744, 1974.
11.
LudererR.C., OpipariM.I., PerrottaA.L.: Treatment of metastatic renal cell carcinoma: Review of experience and world literature. J. Am. Osteopath. Assoc, 77: 590–603, 1978.
12.
MatulichD.T., SpindlerB.G., SchambelanM., BaxterJ.D.: Mineralcorticoid receptors in human kidney. J. Clin. Endocrinol. Metab., 43: 1170–1174, 1976.
13.
MoralesA., KirulutaG., LottS.: Hormones in the treatment of metastatic renal cancer. J. Urol., 114: 692–693, 1975.
14.
PaineC.H., WrightF.W., EllisF.: The use of progestogen in the treatment of metastatic carcinoma of the kidney and uterine body. Br. J. Cancer, 24: 277–282, 1970.
15.
TalleyR.W.: Chemotherapy of adenocarcinoma of the kidney. Cancer, 32: 1062–1065, 1973.
